FDA expands approval for Argenx's VYVGART to treat all adult generalized myasthenia gravis patients.

The FDA has approved an expanded label for Argenx's drug VYVGART, allowing its use for all adult patients with generalized myasthenia gravis (gMG), including all serotypes. This broadens the patient pool significantly and supports Argenx's growth strategy. The approval follows positive Phase 3 trial results and is expected to increase the drug's market potential, with analysts forecasting an 18% expansion in addressable patients and a franchise growing over $5 billion annually. Argenx shares rose following the news, reflecting investor optimism about the drug's commercial prospects.